Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury

Journal of Trauma - Injury, Infection and Critical Care

Volumn 69, Issue 3, 2010, Pages 579-583

  Hamrick, Mark W ^a   Arounleut, Phonepasong ^a   Kellum, Ethan ^a   Cain, Matthew ^a   Immel, David ^b   Liang, Li Fang ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SAVANNAH RIVER NATIONAL LABORATORY   (United States)

^c MetaMorphix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; MYOSTATIN; RECOMBINANT MYOSTATIN PROPEPTIDE; UNCLASSIFIED DRUG; MSTN PROTEIN, MOUSE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE REGENERATION; BONE REMODELING; CALLUS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; FIBULA OSTEOTOMY; HISTOLOGY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCLE INJURY; MUSCLE MASS; MUSCLE REGENERATION; MUSCULOSKELETAL INJURY; MYOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; STAINING; TREATMENT OUTCOME; ANIMAL; BONE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FRACTURE; INJURY; MUSCLE; OSTEOTOMY; PENETRATING TRAUMA; WOUND HEALING;

ANIMALS; BONE AND BONES; BONE REGENERATION; DISEASE MODELS, ANIMAL; FRACTURES, BONE; MALE; MICE; MUSCLES; MYOSTATIN; OSTEOTOMY; RECOMBINANT PROTEINS; WOUND HEALING; WOUNDS, PENETRATING; X-RAY MICROTOMOGRAPHY;

EID: 77957599249     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181c451f4     Document Type: Article

References (37)

1. Gerstenfeld L, Einhorn T. Developmental aspects of fracture healing and the use of pharmacological agents to alter healing. J Musculoskelet Neuronal Interact. 2003;3:297-303. (Pubitemid 38111612)
2. Stein A, Perren S, Cordey J, Kenwright J, Mosheiff R, Francis MJ. The muscle bed-a crucial factor in fracture healing: a physiological concept. Orthopedics. 2002;25:1379-1383.
3. Landry P, Marino A, Sadasivan K, Albright J. Effect of soft-tissue trauma on the early periosteal response of bone to injury. J Trauma. 2000;48:479-483.
4. Utvåg SE, Iversen KB, Grundnes O, Reikerås O. Poor muscle coverage delays fracture healing in rats. Acta Orthop Scand. 2002;73:471-474.
5. Utvåg SE, Grundnes O, Rindal DB, Reikerås O. Influence of extensive muscle injury on fracture healing in rat tibia. J Orthop Trauma. 2003;17:430-435.
6. Gopal S, Majumder S, Batchelor AG, Knight SL, De Boer P, Smith RM. Fix and flap: the radical orthopaedic and plastic treatment of severe open fractures of the tibia. J Bone Joint Surg Br. 2000;82:959-966.
7. Zacks SI, Sheff MF. Periosteal and metaplastic bone formation in mouse minced muscle regeneration. Lab Invest. 1982;46:405-412.
8. McPherron AC, Lawler AM, Lee S-J. Regulation of skeletal muscle mass in mice by a new TGF-ß superfamily member. Nature. 1997;387:83-90.
9. Lee SJ. Regulation of muscle mass by myostatin. Ann Rev Cell Dev Biol. 2004;20:61-86.
10. Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3: e79.
11. Schuelke M, Wagner K, Stolz L, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682-2688.
12. Zhu J, Li Y, Shen W, et al. Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem. 2007;282:25852-25863.
13. McCroskery S, Thomas M, Platt L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci. 2005;118(Part 15):3531-3541.
14. Hamrick MW, Shi X, Zhang W, et al. Loss of myostatin function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40:1544-1553.
15. Hamrick MW. Increased bone mineral density in the femora of GDF-8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol. 2003;272:388-391.
16. Hamrick MW, Pennington C, Byron C. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF8 (myostatin). J Orthop Res. 2003;21:1025-1032.
17. Zhang ZL, He JW, Qin YJ, et al. Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families. Osteoporosis Int. 2008;19:39-47.
18. Mitchell A, Wall R. In vivo evaluation of changes in body composition of transgenic mice expressing the myostatin pro-domain using dual energy X-ray absorptiometry. Growth Dev Aging. 2007;70:25-37.
19. Cho T, Gerstenfeld L, Einhorn T. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res. 2002;17:513-520.
20. Nagamine T, Imamura T, Ishidou Y, et al. Immunohistochemical detection of activin A, follistatin, and activin receptors during fracture healing in the rat. J Orthop Res. 1998;16:314-321.
21. Kellum E, Starr H, Arounleut P, et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 2009;44:17-23.
22. Thies RS, Chen T, Davies MV, et al. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors. 2001;18:251-259.
23. Hill JJ, Davies MV, Pearson AA, et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem. 2002;277:40735-40741.
24. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. Myostatin-propeptide mediated amelioration of dystrophic pathophysiology. FASEB J. 2005;19:543-549.
25. Zhao B, Wall R, Yang J. Transgenic overexpression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun. 2005;337:248-255.
26. Gerstenfeld LC, Wronski TJ, Hollinger JO, Einhorn TA. Application of histomorphometric methods to the study of bone repair. J Bone Miner Res. 2005;20:1715-1722.
27. Bialek P, Parkington J, Warner L, et al. Mice treated with a myostatin/GDF-8 decoy receptor, ActRIIB-Fc, exhibit a tremendous increase in bone mass. Bone. 2008;42: S46.
28. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002;52:832-836.
29. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561-571.
30. Wagner KR. Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol. 2005;17:720-724.
31. Benabdallah B, Bouchentouf M, Rousseau J, et al. Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant. 2008;17:337-350.
32. Covey D. Combat orthopaedics: a view from the trenches. J Am Acad Orthop Surg. 2006;14: S10-S17.
33. Owens B, Kragh JF Jr, Macaitis J, Svoboda SJ, Wenke JC. Characterization of open extremity wounds in Operation Iraqi Freedom and Operation Enduring Freedom. J Orthop Trauma. 2007;21:254-257.
34. Covey DC. Blast and fragment injuries of the musculoskeletal system. J Bone Joint Surg Am. 2002;84-A:1221-1234.
35. Gates CB, Karthikeyan T, Fu F, Huard J. Regenerative medicine for the musculoskeletal system based on muscle-derived stem cells. J Am Acad Orthop Surg. 2008;16:68-76.
36. Cho S, Holcomb J, Tieu B, et al. Reproducibility of an animal model simulating complex combat-related injury in a multiple-institution format. Shock. 2009;31:87-96.
37. Cadosch D, Gautschi O, Thyer M, et al. Humoral factors enhance fracture-healing and callus formation in patients with traumatic brain injury. J Bone Joint Surg Am. 2009;91:282-288.